Placenta-derived mesenchymal stem cells ameliorate lipopolysaccharide-induced inflammation in RAW264.7 cells and acute lung injury in rats

WEN YUAN1*, HENG-YA SONG2*, JIE XIONG3, WAN-LI JIANG2, GAN-JUN KANG2, JIE HUANG2 and SONG-PING XIE2

1Department of Laboratory Medicine, Wuhan Children’s Hospital, Wuhan Maternal and Child Healthcare Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430016; 2Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060; 3Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, Hubei 430071, P.R. China

Received September 9, 2019; Accepted April 14, 2020

DOI: 10.3892/mmr.2020.11231

Abstract. Acute lung injury (ALI) is a severe lung syndrome with high morbidity and mortality, due to its complex mechanism and lack of effective therapy. The use of placenta-derived mesenchymal stem cells (pMSCs) has provided novel insight into treatment options of ALI. The effects of pMSCs on lipopolysaccharide (LPS)-induced inflammation were studied using a co-culture protocol with LPS-stimulated RAW264.7 cells. An LPS-induced ALI Sprague-Dawley rat model was developed by intravenously injecting 7.5 mg/kg LPS, and intratracheal instillation of 1x10^7 pMSCs was performed after administration of LPS to investigate the therapeutic potential of these cells. pMSCs ameliorated LPS-induced ALI, as suggested by downregulated pro-inflammatory cytokine tumor necrosis factor-α and increased anti-inflammatory cytokine interleukin-10 in both cell and animal models. Moreover, the protein and leukocyte cells in bronchoalveolar lavage fluid decreased at a rapid rate after treatment with pMSCs. Histopathology demonstrated that pMSCs alleviated the infiltration of inflammatory cells, pulmonary hyperemia and hemorrhage, and interstitial edema. In addition, pMSC reduced the LPS-induced expression of C-X-C motif chemokine ligand 12 in RAW264.7 macrophages and in lung tissue of ALI rats. This demonstrated that pMSCs are therapeutically effective in LPS-induced ALI.

Introduction

Both acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe clinical conditions accompanied by interstitial edema and infiltration of inflammatory cells, which result in progressive acute respiratory failure (1-3). A previous systematic review reported that the mortality rate of pediatric ARDS (PARDs) was 24%, with ~one-quarter of patients developing new morbidities after PARDs due to residual organ dysfunction and complications related to treatments (4,5). Radiation-induced lung injury commonly occurs in patients receiving radiotherapy for thoracic cancer (6). Inhaled corticosteroids and other anti-inflammatory drugs are effective in patients with inflammatory lung disorders. However, their long-term use is associated with severe side effects (7). While ARDS mortality has moderately declined with improved ventilator management and fluid management, it has remained as high as 20 and 40% in clinical studies, respectively (2).

The therapeutic potential of mesenchymal stem cells (MSCs) for ARDS has been evaluated in previous clinical trials (8,10). It was demonstrated that a single intravenous infusion of allogeneic bone marrow (BM)-MSCs was well tolerated in nine patients with moderate to severe ARDS in a previous clinical trial (NCT01775774) (8). However, the clinical use of BM-MSCs was hindered by low cell numbers on harvest (9). Another previous clinical study (NCT01902082) reported that intravenous administration of allogeneic adipose-derived MSCs was safe and feasible but inefficient in the treatment of ARDS (10). Compared with BM-MSCs, placenta-derived MSCs (pMSCs) are more easily obtained in larger numbers (11,12). As pMSCs have similar properties and functions as BM-MSCs, these cells have become a promising alternative source of MSCs in research and clinical applications (12). A previous study demonstrated that treatment with pMSCs was protective against the development of bronchiolitis obliterans in a murine model.
model (13). Evidence has shown that the progress of pulmonary inflammation is closely related to the phenotype and function of macrophages (14,15). pMSCs can regulate macrophage differentiation from the pro-inflammatory type to the anti-inflammatory type (16). However, to the best of the authors’ knowledge, the therapeutic potential of pMSC delivery in ALI treatment has not been studied to date.

C-X-C motif chemokine 12 (CXCL12) belongs to the family of CXC chemokines. Diallyl trisulfide, a garlic-derived organosulfur compound, markedly reduced the expression of CXCL12 in lipopolysaccharide (LPS)-stimulated BV2 microglial cells, demonstrating its anti-inflammatory effects against LPS stimulation (17). The administration of CXCL12-neutralizing antibodies delayed disease onset or prevented disease progression in cancer, inflammatory bowel diseases and ALI (18). Thus, CXCL12 may act as an inflammatory cytokine in LPS-induced ALI.

ALI and ARDS often develop as a complication of severe sepsis, particularly after infection with Gram-negative bacteria (19). LPS-induced endotoxemia triggers the secretion of pro-inflammatory cytokines and is extensively used to establish an ALI animal model (20). In the present study, pMSCs were used to treat LPS-induced RAW264.7 macrophages and the effects of intratracheal delivery of pMSCs on LPS-induced ALI in Sprague-Dawley rats were investigated.

Materials and methods

Isolation and culture of pMSCs. pMSCs were isolated from chorionic villi in placenta of Sprague-Dawley rats, which were anesthetized by intraperitoneal anesthesia with 2% pentobarbital sodium (100 mg/kg). Briefly, placental tissue was dissected, then thoroughly washed with ice-cold sterile PBS (Gibco; Thermo Fisher Scientific, Inc.). The suspension was filtered using a 200 mesh sieve, collected and centrifuged at 1,000 x g for 10 min at 4˚C. The supernatant was discarded, and the pellet was resuspended in dMeM containing 10% FBS and plated in T25 Flasks (corning, inc.) in a 5% co2 air incubator at 37˚C. The cell density was adjusted to 3x10⁶/ml and the cells were laid in the glass bottom dishes specially designed for laser confocal microscopy. Cells were fixed with 4% paraformaldehyde for 20 min at 4˚C and permeabilized with 0.1% Triton X-100 for 10 min, blocked with 3% BSA, and sealed for 60 min at room temperature. After incubation overnight with anti-CD44 antibody (1:200; cat. no. ab189524; Abcam), the cells were rinsed thoroughly and treated with anti-rabbit antibodies (1:200; cat. no. BA1032; Boster Biological Technology), respectively. Nuclei were stained using 0.3 µM DAPI (cat. no. CI002; Beyotime Institute of Biotechnology).

Osteogenic and adipogenic differentiation of pMSCs. The third generation of pMSCs were seeded at 1x10⁶ cells/cm² on a 24-well plate (Merck KGaA). When the density of cells reached 80%, the complete medium was removed and cells were induced with an osteogenic induction medium (DMEM with 10% FBS; 0.1 µM dexamethasone; 10 mM β-glycerophosphate sodium; 50 µM ascorbic acid). Cells were cultured for 3 weeks and the medium was changed every 72 h. After 3 weeks, differentiated pMSCs were stained with aqueous 0.5% (v/v) Alizarin Red S (Beijing Solarbio Science & Technology co, Ltd.) for 30 min at room temperature. For adipogenic induction, the cells were plated in DMEM supplemented with 10% FBS, 200 µM indomethacin, 1 µM dexamethasone, 0.5 mm isobutyl methylxanthine and 0.1% lipopolysaccharide (LPS) at 37˚C. RAW264.7 cells were then seeded and cultured in six-well plates at a density of 5x10⁵ cells/well, followed by treatment with LPS at different concentrations (1, 2 or 5 µg/ml) for different time periods (0, 0.5, 1, 2, 4 or 24 h), and tumor necrosis factor-α (TNF-α) levels were detected by ELISA (cat. no. E-EL-M0049c; Elabscience Biotechnology, Inc.) to determine if the LPS-induced RAW264.7 macrophage inflammatory model was established. To detect the therapeutic effects of pMSCs in the RAW264.7 macrophage inflammation model in vitro, RAW264.7 cells and pMSCs were co-cultured at 37˚C for 48 h in two chambers using Millicell (Corning Inc.) to prevent contact between the cells.

TNF-α and interleukin (IL)-10 ELISA. Cell-free supernatants were collected, and IL-10 and TNF-α levels were measured using IL-10 (cat. no. SEA056Ra, Wuhan USCN Business Co., Ltd.) and TNF-α (cat. no. E-EL-R0019c; Elabscience Biotechnology, Inc.) ELISA kits according to the manufacturers’ instructions.

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was isolated from RAW264.7 cells using TRIpure (cat. no. RN0101; Aidlab Biotechnologies Co., Ltd.) and reverse transcribed into cDNA using the HiScript Reverse Transcriptase (RNase H) (cat. no. R101-01/02; Vazyme Biotech Co., Ltd.) at the following conditions: 25˚C 5 min; 50˚C 15 min; 85˚C 5 min. PCR amplification was independently
performed with a SYBR Green PCR kit (cat. no. Q111-02; Vazyme Biotech Co., Ltd.) using the Applied Biosystems 7500 real-time PCR system (Applied Biosystems QuantStudio 6; Applied Biosystems; Thermo Fisher Scientific, Inc.) in triplicate. The thermocycling conditions of the PCR were as follows: 5 min at 95˚C, 15 sec at 95˚C and 1 min at 60˚C for 40 cycles, then 5 min at 72˚C. The reaction specificity was controlled by post-amplification melting curve analysis and gel electrophoresis. The expression fold changes were analyzed using the 2ΔΔcq relative quantification method (21). Primer sequences were as follows: IL-10-forward, 5'-GGAGGAGAATTCGTGAGCT-3'; TNF-α-forward, 5'-CGTACGCGATTGTCTATTC-3'; TNF-α-reverse, 5'-CGGACCTCGGAAAGTCTAAG-3'; CXCL12-forward, 5'-TCACACTCTCAAACCTGGCTCCTCA-3'; CXCL12-reverse, 5'-GCCTTTCTCTTCCTTCATGCCTC-3; β-actin-forward, 5'-CAGTGGAGGGGGCCGAGTCTCAT-3' and β-actin-reverse, 5'-TAAGACCTCTATGGCAACAGT-3'.

**Western blotting.** Cells were lysed in RIPA lysis buffer (Beyotime Institute of Biotechnology) on ice. Protein concentrations were determined using the BCA kit (Thermo Fisher Scientific, Inc.). The sample proteins (40 µg/lane) were separated via SDS-PAGE on 15% gels and transferred to a PVDF membrane (EMD Millipore). The membranes were then blocked with TBS containing 5% non-fat dried milk and 0.1% Tween-20 at 4˚C for 2 h. After blocking, the membranes were incubated with a primary anti-CXCL12 antibody (1:1,000; Abcam; cat. no. ab9797) overnight at 4˚C with gentle shaking and subsequently incubated with HRP-conjugated anti-rabbit IgG secondary antibody (1:50,000; Wuhu Boster Biological Technology, Ltd.; cat. no. BA1054) for 2 h at room temperature. The bands were detected using enhanced chemiluminescence western blotting detection reagents (Thermo Fisher Scientific, Inc.). GAPDH (1:1,000; cat. no. AB-P-R 001; Goodhere Biological Technology) was used as a loading control, and the band density was measured using ImageJ (version 1.52a; National Institutes of Health).

**Rat model of ALI.** All animal procedures were approved by The Ethics Committee of Clinical Research, Renmin Hospital of Wuhan University (reference no. WDRY2018-K048). All animal experiments were performed in compliance with the Guidelines for Proper Conduct of Animal Experiments established by the Science Council. A total of 15 adult male Sprague-Dawley rats (aged 6-8 weeks; weight, 280-350 g) were provided by Hunan SJA Laboratory Animal Co., Ltd. The rats were housed in a specific pathogen-free environment at 18-26˚C in the dark, with 40-70% humidity, and free access to food and water. These rats were randomly divided into three groups: A normal control (NC) group injected with 0.5 ml PBS; an LPS-induced ALI group intravenously receiving 7.5 mg/kg LPS dissolved in 0.5 ml sterile saline solution (22); and in the LPS + pMSCs group, rats were anesthetized using 2% pentobarbital (30 mg/kg), and 1x10^7 pMSCs intratracheal instillation was performed after administration of LPS for 1 h (pMSCs group). After 3 days, the lung tissue and the bronchoalveolar lavage fluid (BALF) samples were collected (23,24). There were five rats in each group.

**Analysis of BALF.** BALF was collected and centrifuged at 600 x g for 5 min at 25˚C, for quantification of total protein content in the BALF supernatant standard BALF collection was performed, as described previously (25). The protein concentration was measured using a BCA Protein Assay kit (Beyotime Institute of Biotechnology) following the manufacturer's instructions. BALF cytokine levels were examined using IL-10 (cat. no. SEA056Ra, Wuhan USCN Business Co., Ltd.) and TNF-α (cat. no. E-EL-R0019c, Elabscience Biotechnology, Inc.) ELISA kits.

**Cell counts and Giemsa staining.** The number of white blood cells in BALF was counted using a counting plate. The alveolar lavage fluid was coated with glass slides and stained with Giemsa (reagent 1 solution for 1 min and reagent 2 for 6-8 mins at room temperature), then the stained cells were observed with a light microscope at magnification, x100 and x200.

**Histopathological observation of lungs.** The lower lobe of the right lung was collected from the rats, fixed in 10% formaldehyde solution for 48 h at room temperature, embedded in paraffin, dehydrated, cut into 5-µm sections and observed under an optical microscope (magnification, x100 and x200) after hematoxylin-eosin (HE) staining for 5 min at room temperature.

**Immunohistochemical analysis.** Paraaffin-embedded tissues were sectioned at 5 µm, mounted onto glass slides and dewaxed, then rehydrated in a descending alcohol gradient (100, 95, 90, 80, 70 and 50%). Antigen retrieval was performed by microwaving at high power in 10 mM sodium citrate buffer, pH 6.0 for 20 min. To block the non-specific binding of antibodies, each slide was blocked with 10% normal goat serum (cat. no. AR1009; Boster Biological Technology) for 30 min at room temperature. Immunostaining was performed by incubation with an anti-CXCL12 antibody (1:200, cat. no. ab9797; Abcam) at 4˚C overnight. Slides were then washed in PBS and incubated with secondary antibody (anti-rabbit detection system: 1:200; cat. no. GB23303; Wuhan Servicebio Technology Co., Ltd.) for 30 min at 37˚C. Tissues were stained with 3, 3-diaminobenzidine for 5 min at room temperature and counterstained with hematoxylin for 1 min at room temperature. Photomicrographs were taken using an Olympus BX53 microscope (Olympus Corporation), at magnification, x100 and x400. Image Pro Plus version 6.0 (Media Cybernetics, Inc.) was used to determine staining intensity.

**Statistical analysis.** All data were analyzed using GraphPad Prism version 5.0 software (GraphPad Software, Inc.) and presented as the mean ± SD of three independent experiments. One-way ANOVA followed by Newman-Keuls Multiple Comparison post hoc test were used when appropriate. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Isolation and identification of pMSCs.** pMSCs from rat embryos were isolated and cultured, which were passed to the P2 generation and adherent in a serum-containing medium and showed a spindle-like shape (Fig. 1A). Phenotypic analysis
was carried out by flow cytometry. CD44, CD90 and CD29 were 97.87, 97.58 and 96.02%, respectively, while CD31, CD45, CD11b/c were negative (Fig. 1B). This was consistent with the expected pMSC phenotype CD44⁺CD90⁺CD29⁺CD31⁻CD45⁻CD11b/c⁻. Subsequently, immunofluorescence staining was used to evaluate specific expression of the CD44 marker in pMSCs (Fig. 1C). The primary antibody was replaced with PBS in the control group, while the CD44 antibody of anti-mouse was replaced in the experimental group. Although the staining result was similar in non-specific nuclear staining of both groups, specific CD44 staining in the experimental group was much stronger than that in the control group. Thus, cells isolated from rat embryos were indeed pMSCs that expressed CD44. The potential pluripotent ability of pMSCs was confirmed by osteogenic and adipogenic differentiation in vitro (Fig. 1D), this indicated that pMSCs have multilineage differentiation ability in the cultured condition.

Therapeutic effects of pMSCs in RAW264.7 macrophage inflammation model in vitro. Before establishing the inflammatory model, the optimally induced concentration of LPS was evaluated using ELISA and to establish an LPS-induced RAW264.7 macrophage inflammation model. When the concentration of the pro-inflammatory cytokine TNF-α reached the maximum, the optimum condition was achieved. As presented in Fig. 2A, the optimal concentration was 5 µg/ml with co-culturing for 4 h. The inflammation model of RAW264.7 macrophages by this optimal condition for 4 h was
then induced. A total of three groups were formed: RAW264.7 cells as the control (NC group), RAW264.7 cells treated with LPS (LPS group), and RAW264.7 cells treated with LPS + pMSCs (pMSCs group). The expressions of cytokines TNF-α and IL-10 were detected. As presented in Fig. 2B, pMSCs reduced the expression of TNF-α and increased IL-10 in the cell inflammatory model. These results provide evidence for the direct involvement of the therapeutic effect of pMSCs in LPS-induced injury.

**Influence of pMSCs on lung histopathology.** An LPS-induced ALI animal model was established to determine whether pMSCs had a protective effect against LPS-induced ALI in vivo. The histopathology of rat lung tissue from each group was examined using HE staining (Fig. 3A). The HE staining of lung sections before administration of LPS showed no obvious lesions in the NC group. However, after LPS was administered, typical histological features of ALI were observed in the LPS group, including diffuse alveolar injury, massive pleomorphic leukocytes in the stroma, obvious hyperemia and hemorrhage in alveolar, remarkable interstitial edema, and thickened alveolar septum. Although the treatment of pMSCs improved the lung histopathology by reducing neutrophil infiltration and alleviating interstitial edema, there was still challenge compared with that of the NC group.

**Effect of pMSCs on BALF inflammatory cells and proteins.** As the hallmark of ALI, indicators of vascular leakage in BALF were assessed, typically the total leukocyte cell number and total protein concentration, which are common indicators to evaluate the severity of alveolar-capillary membrane injury. The pMSCs injected into the LPS-induced ALI rats caused a decrease in the balance of inflammatory cells and the total cell count was significantly reduced compared with the LPS group.
The protein in BALF was markedly increased in rats that received LPS compared with untreated rats (P<0.05 vs. NC group). Moreover, a significant decrease in the protein of BALF was observed in the pMS cs group (P<0.05 vs. LPS group; Fig. 3d).

Reduced TNF-α and increased IL-10 by pMSCs. TNF-α and IL-10 expression levels in BALF of the three groups were determined using ELISA. The average of the data was acquired after multiple measurements. The administration of pMSCs led to decreased TNF-α and increased IL-10 (Fig. 3e) during LPS-induced ALI, which suggested that pMSCs are an effective therapy for LPS-induced ALI.

pMSC downregulates CXCL12 in LPS-induced ALI. In our previous studies it was demonstrated that the activation of the CXCL12/CXCR4 axis played an important role in the metastasis and drug resistance in lung cancer (26-28). Moreover, CXCL12 could serve as pro-inflammatory chemokines as was reported in some previous studies (17,18). To further investigate the mechanism underlying the effect of pMSCs on LPS-induced ALI, mRNA levels and protein expression of CXCL12 in LPS-induced RAW264.7 cells and LPS-induced ALI were measured. As presented in Fig. 4A and B, the LPS group showed a significantly higher expression of CXCL12 compared with the NC group (P<0.001). However, treatment with pMSCs reversed this effect, suggesting that pMSCs reduced the expression of CXCL12 in the RAW264.7 macrophage inflammatory model (P<0.05). To demonstrate the effects of pMSCs on histopathological changes in lung tissues in LPS-induced ALI rats, histological analysis was carried out using immunohistochemistry. The LPS group displayed very high expression of CXCL12, while the pMSC group showed a marked reduction of CXCL12 (Fig. 4C and D). These data indicated that pMSC administration reduced the LPS-induced expression of CXCL12 in RAW264.7 macrophage and in lung tissue of ALI rats. Therefore, pMSCs significantly regulated levels of pro-inflammatory cytokines, such as TNF-α (P<0.05) and anti-inflammatory IL-10 (P<0.05), as well as accumulation of inflammatory cells and protein concentration in BALF. This suggested that pMSCs were effective in attenuating LPS-induced ALI.

Discussion

Despite the increased understanding of the pathogenesis of ALI and ARDS, the underlying mechanism remains to be investigated. Currently, there is evidence suggesting that macrophages are key factors in the pathogenesis of ALI/ARDS (29). Macrophages can be divided into pro-inflammatory M1-type and anti-inflammatory M2-type macrophages. While the M1-type can secrete TNF-α cytokines to promote the progress of inflammation, the M2-type can secrete IL-10 to inhibit the progress of inflammation (30). A previous study suggested that
regulating the function of macrophages might be a promising therapeutic strategy against ALI/ARDS (14). The present study demonstrated that pMSCs could inhibit the inflammatory response by decreasing the secretion of TNF-α cytokines and increasing the IL-10 secretion in an LPS-induced RAW264.7 macrophage inflammatory model.

In the present study, pMSCs could inhibit the inflammatory response of LPS-induced RAW264.7 macrophages. Thus, the focus of the present study was to evaluate whether pMSCs had an effect on ALI in rats and how this therapeutic effect could be exerted. An ALI rat model was established using intravenous instillation of LPS. Pretreatment with pMSCs significantly reduced LPS-induced lung pathological changes, levels of pro-inflammatory cytokines and infiltration of pleomorphic leukocytes and total protein in BALF. Previous studies demonstrated that MSCs could be transplanted into rabbits or humans with beneficial effects and without immunological rejection (31,32). In the present study, pMSC administration did not cause any adverse effect in rats and led to decreased TNF-α and increased IL-10 levels during LPS-induced ALI. A previous study demonstrated that IL-10 overexpression in umbilical cord MSCs enhanced their effects in E. coli pneumosepsis and increased macrophage function, which illustrated their therapeutic potential for infection-induced ARDS (33). Recently, it has been reported that erythropoietin produces protective effects against ALI in rats by increasing the levels of anti-inflammatory cytokine IL-10 (34). The present study demonstrated that pMSCs increased the IL-10 secretion of LPS-induced RAW264.7 macrophages. In addition, pMSC treatment increased IL-10 levels, which led to beneficial effects on LPS-induced ALI and enhanced the macrophage function. pMSCs reduced the LPS-induced expression of CXCL12 in RAW264.7 macrophages and in lung tissue of ALI rats. Therefore, CXCL12 may act as an inflammatory cytokine in LPS-induced ALI and pMSCs could have a therapeutic effect on ALI through inhibition of CXCL12 expression.

In the present study, TNF-α expression was used to characterize the LPS-induced RAW264.7 macrophage inflammatory model. BALF inflammatory cells and protein, lung histopathology and pro-inflammatory cytokine TNF-α were used to confirm establishment of the LPS-induced ALI rat model. Although TNF-α is the most representative and commonly used inflammatory cytokine (35-37), other inflammatory cytokines, such as IL-1β (35), nuclear factor-κB (36) and IL-6 (37) should also be assessed to further characterize LPS-induced ALI. Several previous studies suggested that macrophages are a key component in the initiation and maintenance of the inflammatory response in ALI (14,38,39). Thus, modulation of macrophage function might provide new therapeutic modalities for ALI. The LPS-induced RAW264.7 macrophage inflammatory model is a commonly used inflammatory model (40,41). The results of the present study demonstrated that pMSCs could inhibit the inflammatory response of LPS-induced RAW264.7 macrophage inflammatory model in vitro. In accordance with other previous studies (42-44), the NC, LPS and LPS + pMSC groups were used both in vitro and in vivo. The effects of pMSC administration without LPS stimulation have not been evaluated in the present study.

In summary, the present study demonstrated that pMSCs reduced inflammation and protected against lung injury in the LPS-induced ALI rat model. However, the mechanisms and long-term effects need to be studied further.
Acknowledgements
Not applicable.

Funding
The present study was supported by The National Natural Foundation of China (grant no. 81801954).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
SX and JH conceived the study and designed the experiments. WY and HS performed the experiments and drafted the manuscript. JX, WJ and GK made substantial contributions to data analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All animal procedures were approved by The Ethics Committee of Clinical Research, Renmin Hospital of Wuhan University (reference no. WDRY2018-K048). All animal experiments were performed in compliance with the Guidelines for Proper Conduct of Animal Experiments established by the Science Council.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L and Slutsky AS: Acute respiratory distress syndrome: The Berlin Definition. JAMA 307: 2526-2533, 2012.
2. Matthay MA, Ware LB and Zimmerman GA: The acute respiratory distress syndrome. J Clin Invest 122: 2731-2740, 2012.
3. Butt Y, Kurdowska A and Allen T: Acute lung injury: A systematic review and meta-analysis. J Intensive Care Med 34: 563-571, 2019.
4. Wong JJ, Jit M, Sultana R, Mok YH, Yeo JG, Koh JWJ, Loo TF, and Lee JH: Mortality in pediatric acute respiratory distress syndrome survivors. Crit Care Med 43: 1731-1738, 2015.
5. Reis MM, Coste E, Yang X, Yuan E, Guo Y, Yang X, et al: Mesenchymal stem cells ameliorate acute lung injury in rats. Braz J Med Biol Res 49: e5008, 2016.
6. Shrivastava M, Saha S, and Das S: Mesenchymal stem cell therapy for acute lung injury induced by lipopolysaccharide in mice. Eur Rev Med Pharmacol Sci 19: 857-865, 2015.
7. Buttenschoen K, Kornmann M, Berger D, Leder G, Beger HG and Manns MP: Toll-like receptor 4 and cXcr4 pathway blockade. J Immunol 186: 7943-7950, 2010.
8. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Callie C, Lee JW, et al: Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 3: 24-32, 2015.
9. Zhu Y, Liu T, Song K, Fan X, Ma X and Cui Z: Adipose-derived stem cell: A better stem cell than BMSC. Cell Biochem Funct 26: 664-675, 2008.
10. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou R, Cheng B and Xu F: Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebo-controlled pilot study. Respir Res 15: 39, 2014.
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: The role of macrophages in the pathogenesis of ALI/ARDS. Mediators Inflamm 2018: 1264913, 2018.
12. VellaSamy S, Sandrasagaran P, Vidyadaran S, George E and Ramasamy R: Isolation and characterisation of mesenchymal stem cells derived from human placenta tissue. World J Stem Cells 4: 53-61, 2012.
13. Zhao Y, Gillen JR, Harris DA, Kron IL, Murphy MP and Lau CL: Treatment with placenta-derived mesenchymal stem cells mitigates development of bronchiolitis obliterans in a murine model. J Thorac Cardiovasc Surg 147: 1666-1671.e1665, 2018.
14. Huang X, Xia H, Zha J and Zhan G: 3T3-L1 macrophages in the pathogenesis of ALI/ARDS. Mediators Inflamm 2018: 1264913, 2018.
15. Wynn TA, Chawla A and Pollard JW: Macrophage biology in development, homeostasis and disease. Nature 494: 445-455, 2013.
16. Aboumarre MH, Al Jumah MA, Kalionis B, Jawdat D, Al Khaldi A, Abomaray FM, Fatani AS, Chamley LW and Knawy BA: Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Rev Rep 9: 560-641, 2013.
17. Lee HH, Jeong JW, Hong SH, Park C, Kim BW and Choi YH: Diallyl triisulfide suppresses the production of lipopolysaccharide-induced inflammatory mediators in BV2 microglia by decreasing the NF-kappaB pathway activity associated with toll-like receptor-4 and CXCR4 pathway blockade. J Cancer Prev 23: 134-140, 2018.
18. Janssens R, Struyf S and Proost P: Pathological roles of the homeostatic chemokine CXCL12. Cytokine Growth Factor Rev 44: 51-68, 2018.
19. Buttenschokon K, Kornmann M, Berger D, Leder G, Beger HG and Vasilescu C: Endotoxemia and endotoxin tolerance in patients with ARDS. Langenbecks Arch Surg 393: 473-478, 2008.
20. Chen H, Bai C and Wang X: The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Rev Respir Med 4: 773-783, 2010.
21. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
22. Li G, Zhou CL, Zhou QS and Zou HD: Galantamine protects against lipopolysaccharide-induced acute lung injury in rats. Braz J Med Biol Res 49: e5008, 2016.
23. Zhao YF, Luo YM, Xiong W, Ding W, Li YR, Zhao W, Zeng HZ, and Lee JH: Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical study. Molecular and Cellular Endocrinology 386: 102-107, 2014.
24. Han S, Wang X, Zhang H, Li Q, and Ling L: Mesenchymal stem cells ameliorate acute lung injury in mice. Braz J Med Biol Res 49: e5008, 2016.
25. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, Pipeling MR, Brower RG, Tuder RM, Dickey JF and King LS: CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Thorac Cardiovasc Surg 147: 1668-1671.e1665, 2018.
26. Buttenschoen K, Kornmann M, Berger D, Leder G, Beger HG and Vasilescu C: Endotoxemia and endotoxin tolerance in patients with ARDS. Langenbecks Arch Surg 393: 473-478, 2008.
27. Chen H, Bai C and Wang X: The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. Expert Rev Respir Med 4: 773-783, 2010.
28. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
29. Li G, Zhou CL, Zhou QS and Zou HD: Galantamine protects against lipopolysaccharide-induced acute lung injury in rats. Braz J Med Biol Res 49: e5008, 2016.
30. Zhao Y, Luo YM, Xiong W, Ding W, Li YR, Zhao W, Zeng HZ, Gao HC and Wu XL: Mesenchymal stem cell-based FGF2 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Eur Rev Med Pharmacol Sci 19: 857-865, 2015.
31. Li JW and Wu X: Mesenchymal stem cells ameliorate LPS-induced acute lung injury through KGF promoting alveolar fluid clearance of alveolar type II cells. Eur Rev Med Pharmacol Sci 19: 2368-2378, 2015.
32. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, Pipeling MR, Brower RG, Tuder RM, Dickey JF and King LS: CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Thorac Cardiovasc Surg 147: 1668-1671.e1665, 2018.
33. Xie S, Tu Z, Xiong J, Kang G, Zhao L, Hu W, Tan H, Tembo KM, Ding Q, Deng X, et al: CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Oncol Rep 37: 921-928, 2017.
34. Tu Z, Xie S, Xiong J, Liu Y, Yang X, Tembo KM, Huang J, Hu W, Xing H, Pan S, et al: CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer. Int J Oncol 50: 505-514, 2017.
35. Xie S, Zeng W, Fan G, Huang J, Kang G, Geng Q, Cheng B, Wang W and Dong P: Effect of CXCL12/CXCR4 on increasing the metastatic potential of non-small cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression. Oncol Lett 7: 941-947, 2014.
29. Johnston lK, Rims CR, Gill SE, McGuire JK and Manicone AM: Pulmonary macrophage subpopulations in the induction and resolution of acute lung injury. Am J Respir Cell Mol Biol 47: 417-426, 2012.

30. Zheng G, Ge M, Qiu G, Shu Q and Xu J: Mesenchymal stromal cells affect disease outcomes via macrophage polarization. Stem Cells Int 2015: 989473, 2015.

31. Mokhber Dezfooli MR, Jabbari Fakhr M, Sadeghian Chaleshtori S, Dehghan MM, Vajhi A and Mokhtari R: Intrapulmonary autologous transplant of bone marrow-derived mesenchymal stromal cells improves lipopolysaccharide-induced acute respiratory distress syndrome in rabbit. Crit Care 22: 353, 2018.

32. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L and Hofmann T: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 99: 8932-8937, 2002.

33. Jerkic M, Masterson C, Ormesher L, Gagnon S, Gnyal S, Rabani R, Otlakowski G, Zhang H, Kavanagh BP and Laffey JG: Overexpression of IL‑10 enhances the efficacy of human umbilical-cord-derived mesenchymal stromal cells in E. coli Pneumosepsis. J Clin Med 8: E847, 2019.

34. Zhang X and Dong S: Protective effects of erythropoietin towards acute lung injuries in rats with sepsis and its related mechanisms. Ann Clin Lab Sci 49: 257-264, 2019.

35. Badamjav R, Sonom D, Wu Y, Zhang Y, Kou J, Yu B and Li F: The protective effects of Thalictrum minus L. on lipopolysaccharide-induced acute lung injury. J Ethnopharmacol 248: 112355, 2020.

36. Liu J, Chang G, Huang J, Wang Y, Ma N, Roy AC and Shen X: Sodium butyrate inhibits the inflammation of lipopolysaccharide-induced acute lung injury in mice by regulating the toll-like receptor 4/nuclear factor κB signaling pathway. J Agric Food Chem 67: 1674-1682, 2019.

37. Lu Y, Xu D, Liu J and Gu L: Protective effect of sophorcarpine on lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol 70: 180-186, 2019.

38. Aggarwal NR, King LS and D'Alessio FR: Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol 306: L709-L725, 2014.

39. Lomas-Neira J, Chung CS, Perl M, Gregory S, BiW and Ayala A: Role of alveolar macrophage and migrating neutrophils in hemorrhage-induced priming for ALI subsequent to septic challenge. Am J Physiol Lung Cell Mol Physiol 290: L51-L58, 2006.

40. Yang H, Lu Z, Huo C, Chen Y, Cao H, Xie P, Zhou H, Liu D, Liu J and Yu L: Liang-Ge-San, a classic traditional Chinese medicine formula, attenuates lipopolysaccharide-induced acute lung injury through up-regulating miR-21. Front Pharmacol 10: 1332, 2019.

41. Tang J, Diao P, Shu X, Li L and Xiong L: Quercetin and quercitrin attenuates the inflammatory response and oxidative stress in LPS-induced RAW264.7 cells: In vitro assessment and a theoretical model. Stem Cells Res Ther 10: 7039802, 2019.

42. Luo XY, Meng XJ, Cao DC, Wang W, Zhou K, Li L, Guo M and Wang P: Transplantation of bone marrow mesenchymal stromal cells attenuates liver fibrosis in mice by regulating macrophage subtypes. Stem Cell Res Ther 10: 16, 2019.

43. Feng Y, Xu Q, Yang Y, Shi W, Meng W, Zhang H, He X, Sun M, Chen Y, Zhao J, et al: The therapeutic effects of bone marrow-derived mesenchymal stromal cells in the acute lung injury induced by sulfur mustard. Stem Cell Res Ther 10: 90, 2019.

44. Liu F, Qiu H, Xue M, Zhang S, Zhang X, Xu J, Chen J, Yang Y and Xie J: MSC-secreted TGF-β regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway. Stem Cell Res Ther 10: 345, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.